• Publications
  • Influence
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
In June 2005, an ad hoc Expert Committee formed by the Pituitary Society convened during the 9th International Pituitary Congress in San Diego, California. Members of this committee consisted ofExpand
A consensus on criteria for cure of acromegaly.
OBJECTIVE The Acromegaly Consensus Group met in April 2009 to revisit the guidelines on criteria for cure as defined in 2000. PARTICIPANTS Participants included 74 neurosurgeons andExpand
Structure, expression, and function of human pituitary tumor-transforming gene (PTTG).
Despite advances in characterizing the pathophysiology and genetics of pituitary tumors, molecular mechanisms of their pathogenesis are poorly understood. Recently, we isolated a transforming geneExpand
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
Context: Biochemical control reduces morbidity and increases life expectancy in patients with acromegaly. With current medical therapies, including the gold standard octreotide long-acting-releaseExpand
Expert consensus document: A consensus on the medical treatment of acromegaly
In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management ofExpand
A Consensus Statement on acromegaly therapeutic outcomes
The 11th Acromegaly Consensus Conference in April 2017 was convened to update recommendations on therapeutic outcomes for patients with acromegaly. Consensus guidelines on the medical management ofExpand
Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas.
We recently cloned a novel pituitary tumor transforming gene (PTTG). Here we report PTTG expression in human pituitary adenomas and in normal pituitary tissue. In situ hybridization revealed PTTGExpand
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
BACKGROUND Many patients with acromegaly do not achieve biochemical control despite receiving high doses of the first-generation somatostatin analogues octreotide or lanreotide. In the PAOLA trial,Expand
Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.
Bromocriptine (BRC) and other dopamine agonist drugs are the first-choice treatment for prolactinomas. However, the major disadvantage is the need for prolonged therapy. We retrospectively studiedExpand
A consensus on the diagnosis and treatment of acromegaly complications
In March 2011, the Acromegaly Consensus Group met to revise and update the guidelines on the diagnosis and treatment of acromegaly complications. The meeting was sponsored by the Pituitary SocietyExpand
...
1
2
3
4
5
...